Method for alteration detection

• US 6,428,964 B1
• Filed: 03/15/2001
• Issued: 08/06/2002
• Est. Priority Date: 03/15/2001
• Status: Expired due to Term

• Current Assignee: Esoterix Genetic Laboratories LLC (Laboratory Corporation Of America Holdings)
• Original Assignee: Exact Sciences Corporation
• Inventors: Shuber, Anthony P.
• Primary Examiner(s): ZITOMER, STEPHANIE W
• Application Number:
  US09/809,713
• Time in Patent Office: 509 Days
• Field of Search: 435/6, 435/196, 536/23.1, 536/23.5, 536/23.7, 536/23.72
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6874 involving nucleic acid arrays, e.g. sequencing by hybridisation
• CPC Class Codes: C12Q 2521/307 Single strand endonuclease
• CPC Class Codes: C12Q 2521/514 Mismatch repair protein
• CPC Class Codes: C12Q 2525/107 incorporating a peptide nucleic acid
• CPC Class Codes: C12Q 2537/113 Heteroduplex formation
• CPC Class Codes: C12Q 2537/143 Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

Methods are provided for detecting an alteration in a target nucleic acid. Methods of the invention are useful for detecting and identifying mutations that are indicative of disease or the predisposition for disease.

Claims

1. A method for detecting an alteration in a target nucleic acid suspected to be in a biological sample, the method comprising the steps of:

a) adding, to a biological sample suspected to contain a target nucleic acid, a plurality of single-stranded nucleic acids that hybridize contiguously to a region of said target nucleic acid if said region is unaltered;

b) adding to said biological sample an agent that degrades single-stranded nucleic acids; and

,

c) detecting an alteration in said target nucleic acid as the presence of a degradation product from steps a) and b) resulting from degradation within said region of said target nucleic acid.

2. The method of claim 1, wherein said alteration is a disease-associated mutation.

3. The method of claim 2, wherein said disease is cancer.

4. The method of claim 2, further comprising the step of determining the identity of said alteration in said target nucleic acid.

5. The method of claim 1, wherein at least one member of said plurality of single-stranded nucleic acids comprises a detectable label.

6. The method of claim 1, wherein said target nucleic acid suspected of being in said biological sample comprises a detectable label.

7. The method of claim 5 or 6, wherein said detectable label is selected from the group consisting of a fluorescent tag, a radioactive isotope, and a molecular weight marker.

8. The method of claim 1, wherein each member of said plurality of single-stranded nucleic acids is between about 8 and about 30 nucleotides long.

9. The method of claim 1, wherein each member of said plurality of single-stranded nucleic acids has an approximately equivalent hybridization melting temperature with said target nucleic acid.

10. The method of claim 1, wherein said target nucleic acid is bound to a solid support.

11. The method of claim 10, wherein the 5′

end of said target nucleic acid is bound to said solid support.

12. The method of claim 10, wherein the 3′

end of said target nucleic acid is bound to said solid support.

13. The method of claim 1, wherein said biological sample comprises a tissue or body fluid.

14. The method of claim 1, wherein said agent is an enzyme.

15. The method of claim 14, wherein said enzyme is selected from the group consisting of S1, MutY, and MutS.

16. The method of claim 1, wherein said agent is a chemical agent.

17. The method of claim 2, wherein said mutation is selected from the group consisting of nucleotide insertions, deletions, rearrangements, transitions, translations, transversions, and substitutions.

18. The method of claim 13, wherein said tissue or body fluid is selected from the group consisting of sputum, pancreatic fluid, bile, lymph, plasma, urine, cerebrospinal fluid, seminal fluid, saliva, breast nipple aspirate, pus, biopsy tissue, fetal cells, and amniotic fluid.

19. The method of claim 13, wherein said tissue or body fluid is a stool sample.

20. The method of claim 1, wherein said alteration is a single nucleotide polymorphism.

21. The method of claim 1, wherein said alteration is inherited.

22. The method of claim 1, wherein said alteration exists as a subpopulation in a heterogeneous sample.